Given that ALK inhibitors have shown efficacy in extracranial IMT [86,87], the recent Pediatric Strategy Forum for ALK inhibition in pediatric malignancies suggested that performing molecular analysis in IMT could aid in the identification of specific fusions [86]. This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.